205 related articles for article (PubMed ID: 9263656)
1. Antiplatelet and antithrombin therapies in the acute coronary syndromes.
Alexander JH; Harrington RA
Curr Opin Cardiol; 1997 Jul; 12(4):427-37. PubMed ID: 9263656
[TBL] [Abstract][Full Text] [Related]
2. Future perspectives on antithrombin and antiplatelet therapies: novel antiplatelet and antithrombin therapies.
Kandzari DE
Rev Cardiovasc Med; 2006; 7 Suppl 3():S43-52. PubMed ID: 17228270
[TBL] [Abstract][Full Text] [Related]
3. Survival of heparins, oral anticoagulants, and aspirin after the year 2010.
Fareed J; Hoppensteadt DA; Fareed D; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
Semin Thromb Hemost; 2008 Feb; 34(1):58-73. PubMed ID: 18393143
[TBL] [Abstract][Full Text] [Related]
4. Antiplatelet agents in acute coronary syndromes.
Eikelboom JW; Anand S
Semin Vasc Med; 2003 Nov; 3(4):403-14. PubMed ID: 15199447
[TBL] [Abstract][Full Text] [Related]
5. Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?
Fareed J; Iqbal O; Cunanan J; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
Int Angiol; 2008 Jun; 27(3):176-92. PubMed ID: 18506123
[TBL] [Abstract][Full Text] [Related]
6. The scientific basis for combined platelet and thrombin-directed pharmacotherapy in acute coronary syndromes.
Becker RC
J Invasive Cardiol; 2000 Dec; 12 Suppl E():E19-24;discussion E25-8. PubMed ID: 11156725
[TBL] [Abstract][Full Text] [Related]
7. [Glycoprotein 2b3a inhibitors for acute coronary syndromes: what the trials tell us].
Elian D; Guetta V
Harefuah; 2003 May; 142(5):350-4, 398. PubMed ID: 12803058
[TBL] [Abstract][Full Text] [Related]
8. [New therapeutic prospects in acute coronary thrombosis].
Roux S
Arch Mal Coeur Vaiss; 1995 Jan; 88(1):91-4. PubMed ID: 7646255
[TBL] [Abstract][Full Text] [Related]
9. Glycoprotein IIb/IIIa antagonists: do they have a role in the management of unstable angina?
Redwood S; Marber M; Jackson G
Int J Clin Pract; 1999 Dec; 53(8):618-22. PubMed ID: 10692757
[TBL] [Abstract][Full Text] [Related]
10. Current antiplatelet therapies: benefits and limitations.
Angiolillo DJ; Guzman LA; Bass TA
Am Heart J; 2008 Aug; 156(2 Suppl):S3-9. PubMed ID: 18657680
[TBL] [Abstract][Full Text] [Related]
11. Prevention of cardiovascular events after acute coronary syndrome.
Wallentin L
Semin Vasc Med; 2005 Aug; 5(3):293-300. PubMed ID: 16123917
[TBL] [Abstract][Full Text] [Related]
12. Advances in the pathogenesis and treatment of acute coronary syndromes.
Thompson CA; Danzell JD; Hanley HG
J La State Med Soc; 1999 May; 151(5):272-7. PubMed ID: 10363482
[TBL] [Abstract][Full Text] [Related]
13. Global patterns of use of antithrombotic and antiplatelet therapies in patients with acute coronary syndromes: insights from the Global Registry of Acute Coronary Events (GRACE).
Budaj A; Brieger D; Steg PG; Goodman SG; Dabbous OH; Fox KA; Avezum A; Cannon CP; Mazurek T; Flather MD; Van De Werf F;
Am Heart J; 2003 Dec; 146(6):999-1006. PubMed ID: 14660991
[TBL] [Abstract][Full Text] [Related]
14. [Use of platelet antiaggregating agents in acute coronary syndromes].
Torres Peláez Mde L; Santiago Arana C
Arch Cardiol Mex; 2002; 72 Suppl 1():S291-5. PubMed ID: 12001865
[TBL] [Abstract][Full Text] [Related]
15. New strategies in the management of acute coronary syndromes.
Fullwood J; Butler G; Smith T; Cox M; Bride W; Mostaghimi Z; Cook PS; Granger BB
Nurs Clin North Am; 2000 Dec; 35(4):877-95. PubMed ID: 11072276
[TBL] [Abstract][Full Text] [Related]
16. Antithrombotic and antiplatelet therapies in relation to risk stratification in patients with non-ST elevation acute coronary syndrome: insights from the Sino-Global Registry of Acute Coronary Events.
Zhang LJ; Chen YD; Song XT; Zhao FH; Lü SZ
Chin Med J (Engl); 2009 Mar; 122(5):502-8. PubMed ID: 19323898
[TBL] [Abstract][Full Text] [Related]
17. Use of antiplatelet agents and anticoagulants for cardiovascular disease: current standards and best practices.
Faxon DP
Rev Cardiovasc Med; 2005; 6 Suppl 4():S3-14. PubMed ID: 17710074
[TBL] [Abstract][Full Text] [Related]
18. Fundamentals of coagulation and glycoprotein IIb/IIIa receptor inhibition.
Ferguson JJ; Waly HM; Wilson JM
Eur Heart J; 1998 Apr; 19 Suppl D():D3-9. PubMed ID: 9597517
[TBL] [Abstract][Full Text] [Related]
19. The emerging role of platelet glycoprotein IIb/IIIa inhibitors in managing high-risk patients with non-ST segment elevation acute coronary syndromes.
Bolognese L
Curr Med Res Opin; 2007 Jun; 23(6):1217-26. PubMed ID: 17559721
[TBL] [Abstract][Full Text] [Related]
20. Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B).
Mukherjee D; Mahaffey KW; Moliterno DJ; Harrington RA; Yadav JS; Pieper KS; Gallup D; Dyke C; Roe MT; Berdan L; Lauer MS; Mänttäri M; White HD; Califf RM; Topol EJ
Am Heart J; 2002 Dec; 144(6):995-1002. PubMed ID: 12486423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
